BACKGROUND: A native arteriovenous fistula (AVF) is recommended for angio access in patients on chronic hemodialysis (HD). Fistula patency has been improved by exposure to Far Infrared light (FIR).
OBJECTIVE: To investigate whether a single FIR treatment could alter blood velocity, AVF diameter or inflammatory markers.
METHODS: Thirty patients with a native AVF in the forearm were included. Each patient was his/her own control. Ultrasound (US) examinations were performed before and after a single FIR treatment.
RESULTS: A single FIR treatment resulted in a significant increase in blood velocity over the AV fistula from a mean of 2.1 ± 1.0 m/s to 2.3 ± 1.0 m/s (p = 0.02). The diameter of the arterialized vein became wider; 0,72 cm ± 0.02 to 0,80 cm ± 0.02, (p = 0.006). The increase in fistula blood velocity correlated positively with base line serum- urate p = 0.004) and the increase in venous diameter with the base line plasma orosomucoid concentration (p = 0.005).
CONCLUSIONS: This study shows that a single FIR treatment significantly increased AVF blood velocity and vein diameter. Thus, one FIR treatment can help maturation of AVF in the early postoperative course.
BesarabA. and DinwiddieL., Changes noted to KDOQI guidelines forvascular access, Nephrol News Issues20(9) (2006), 36.
2.
WayneE.J., BrierM.E. and DwyerA.C., Association of maturation period blood pressure with dialysis access patency, Semin Dial. [Comparative Study]26(1) (2013), 90–96.
3.
SmithG.E., GohilR. and ChetterI.C., Factors affecting the patency of arteriovenous fistulas for dialysis access, J Vasc Surg. [Review]55(3) (2012), 849–855.
4.
KazemzadehG., ModagheghM., RavariH., et al., Primary patency rate of native AV fistula: Long term follow up, Int J Clin Exp Med5(2) (2012), 173–178.
5.
ChengY., ZhangF., ZhuJ., et al., Influence of blood pressure variability on the life of arteriovenous fistulae in maintenance hemodialysis patients, Clin Hemorheol Microcirc62(2) (2016), 129–137.
6.
JacksonA.J., CoatsP. and KingsmoreD.B., Pharmacotherapy to improve outcomes in vascular access surgery: A review of current treatment strategies, Nephrol Dial Transplant. [Review]27(5) (2012), 2005–2016.
7.
SunS., BeitlerJ.J., OhkiT., et al., Inhibitory effect ofbrachytherapy on intimal hyperplasia in arteriovenousfistula, J Surg Res. [Research Support, Non-U.S.Gov’t]115(2) (2003), 200–208.
8.
KruegerK., BendelM., ZaehringerM., et al., Centered endovascular irradiation to prevent postangioplasty restenosis of arteriovenous fistula in hemodialysis patients; Results of a feasibility study, Cardiovasc Radiat Med5(1) (2004), 1–8.
9.
SaranR., DykstraD.M., WolfeR.A., et al., Association between vascular access failure and the use of specific drugs: The Dialysis Outcomes and Practice Patterns Study (DOPPS), Am J Kidney Dis. [Multicenter Study Research Support, Non-U.S. Gov’t Validation Studies]40(6) (2002), 1255–1263.
10.
PalmerS.C., Di MiccoL., RazaavinM.
, et al., Antiplatelet therapy to prevent hemodialysis vascular access failure: Systematic review and meta-analysis, Am J Kidney Dis. [Meta-Analysis Research Support, Non-U.S. Gov’t Review]61(1) (2013), 112–122.
11.
HuijbregtsH.J., BotsM.L., WittensC.H., et al., Hemodialysis arteriovenous fistula patency revisited: Results of a prospective, multicenter initiative, Clin J Am Soc Nephrol. [Comparative Study Multicenter Study Research Support, Non-U.S. Gov’t]3(3) (2008), 714–719.
12.
KimballT.A., BarzK., DimondK.R., et al., Efficiency of the kidney disease outcomes quality initiative guidelines for preemptive vascular access in an academic setting, J Vasc Surg. [Multicenter Study]54(3) (2011), 760–765. discussion 765-766.
13.
FieldM., MacNamaraK., BaileyG., et al., Primary patency ratesof AV fistulas and the effect of patient variables, JVasc Access. [Comparative Study]9(1) (2008), 45–50.
14.
LinC.C., ChangC.F., LaiM.Y., et al., Far-infrared therapy: A novel treatment to improve access blood flow and unassisted patency of arteriovenous fistula in hemodialysis patients, J Am Soc Nephrol. [Randomized Controlled Trial Research Support, Non-U.S. Gov’t]18(3) (2007), 985–992.
15.
LinC.C. and YangW.C., Prognostic factors influencing the patency of hemodialysis vascular access: Literature review and novel therapeutic modality by far infrared therapy, J Chin Med Assoc. [Review]72(3) (2009), 109–116.
16.
LinC.C., YangW.C., ChenM.C., et al., Effect of far infrared therapy on arteriovenous fistula maturation: An open-label randomized controlled trial, Am J Kidney Dis. [Randomized Controlled Trial Research Support, Non-U.S. Gov’t]62(2) (2013), 304–311.
17.
ToyokawaH., MatsuiY., UharaJ., et al., Promotive effects of far-infrared ray on full-thickness skin wound healing in rats, Exp Biol Med (Maywood). [Comparative Study Research Support, Non-U.S. Gov’t]228(6) (2003), 724–729.
18.
DuranteW. and LinC.C., HOming in on arteriovenous fistula survival, Kidney Int. [Comment Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review]74(1) (2008), 9–11.
19.
YuS.Y., ChiuJ.H., YangS.D., et al., Biological effect of far-infrared therapy on increasing skin microcirculation in rats, Photodermatol Photoimmunol Photomed22(2) (2006), 78–86.
20.
LaiC.C., FangH.C., MarG.Y., et al., Post-angioplasty far infrared radiation therapy improves 1-year angioplasty-free hemodialysis access patency of recurrent obstructive lesions, Eur J Vasc Endovasc Surg. [Randomized Controlled Trial Research Support, Non-U.S. Gov’t]46(6) (2013), 726–732.
21.
KelleherD.K. and VaupelP., No sustained improvement in tumor oxygenation after localized mild hyperthermia, Adv Exp Med Biol. [Research Support, Non-U.S. Gov’t]662 (2010), 393–398.
22.
JungF., From hemorheology to microcirculation and regenerative medicine: Fahraeus Lecture 2009, Clin Hemorheol Microcirc45(2-4) (2010), 79–99.
23.
KimH.R., KimH.K. and OhD.J., Serum osteoprotegerin level is associated with degree of arteriovenous fistula stenosis in patients with hemodialysis, Clin Nephrol. [Research Support, Non-U.S. Gov’t]80(5) (2013), 322–327.
24.
LeeT. and Roy-ChaudhuryP., Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis, Adv Chronic Kidney Dis. [Research Support, N.I.H., Extramural Research Support, U.S. Gov’t, Non-P.H.S. Review]16(5) (2009), 329–338.
25.
StrackeS., KonnerK., KostlinI., et al., Over-expression of IGF-related peptides in stenoses of native arteriovenous fistulas in hemodialysis patients, Growth Horm IGF Res. [Comparative Study]17(4) (2007), 297–306.
26.
ProtackC.D., JainA., VasilasP., et al., The influence of metabolic syndrome on hemodialysis access patency, J Vasc Surg. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]56(6) (2012), 1656–1662.
27.
KrishnanE., Inflammation, oxidative stress and lipids: The risk triad for atherosclerosis in gout, Rheumatology (Oxford). [Research Support, Non-U.S. Gov’t Review]49(7) (2010), 1229–1238.
28.
JinM., YangF., YangI., et al., Uric acid, hyperuricemia and vascular diseases, Front Biosci (Landmark Ed). [Review]17 (2012), 656–669.
29.
LinC.C., LiuX.M., PeytonK., et al., Far infrared therapy inhibits vascular endothelial inflammation via the induction of heme oxygenase-1, Arterioscler Thromb Vasc Biol. [Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]28(4) (2008), 739–745.
